Study finds GLP-1 drugs can help curb SUDs
A study published by BMJ found that glucagon-like peptide-1 (GLP-1) drugs could help reduce the risk of various substance use disorders, including for alcohol, cannabis, nicotine, cocaine and opioids. The study examined records of more than 600,000 patients from the Department of Veterans Affairs who had Type 2 diabetes and took a GLP-1 or a sodium-glucose cotransporter-2 inhibitor, or SGLT2, for treatment. Additionally, the study found that people with pre-existing SUDs who took GLP-1 drugs had reduced risks of SUD-related emergency room visits, hospital admissions, overdose, suicide and death.
Related News Articles
Headline
The Department of Health and Human Services Office for Civil Rights released new guidance on statutory and regulatory requirements under 42 CFR Part 2, which…
Headline
The Health Resources and Services Administration announced Sept. 25 that it awarded $89.3 million in grants to expand access to substance use disorder…
Headline
The Substance Abuse and Mental Health Services Administration Sept. 25 announced that it awarded $247.9 million in grants for services expanding access to…
Headline
The Substance Abuse and Mental Health Services Administration announced Sept. 18 that it awarded $42.3 million in grants to states and territories to support…
Blog
To reduce suicide in the healthcare workforce, hospitals and health systems must create an environment where workers feel safe asking for help.By Susan…
Headline
HHS awards $383 million in grants for suicide prevention, other behavioral health efforts on 988 Day
The Department of Health and Human Services announced Sept. 8 through the Substance Abuse and Mental Health Services Administration that it will award $383.4…